The estimated Net Worth of Nevan C Elam is at least $539 Thousand dollars as of 28 December 2023. Mr. Elam owns over 93,843 units of Savara Inc stock worth over $97,200 and over the last 20 years he sold SVRA stock worth over $442,001. In addition, he makes $0 as Independent Director at Savara Inc.
Sign up
Mr. Elam SVRA stock SEC Form 4 insiders trading
Nevan has made over 7 trades of the Savara Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 93,843 units of SVRA stock worth $442,001 on 28 December 2023.
The largest trade he's ever made was selling 93,843 units of Savara Inc stock on 28 December 2023 worth over $442,001. On average, Nevan trades about 7,049 units every 94 days since 2005. As of 28 December 2023 he still owns at least 22,500 units of Savara Inc stock.
You can see the complete history of Mr. Elam stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Nevan Elam biography
Nevan C. Elam serves as Independent Director of the Company. Mr. Elam has served as a member of our Board of Directors since February 2009. Mr. Elam is currently the President, Chief Executive Officer and Chairman of Rezolute Inc. (formerly AntriaBio, Inc.) (OTCQB: RZLT), a biopharmaceutical company focused on developing novel extended release therapies. Prior to his tenure at Rezolute which began in October 2012, Mr. Elam served for three years as the Chief Executive Officer and President of AeroSurgical Ltd., a medical device company operating out of Ireland. Prior to his service with AeroSurgical Ltd., Mr. Elam was Head of the Pulmonary Business Unit and Senior Vice President of Nektar Therapeutics. Earlier in his career he was a founder and Chief Financial Officer of E2open as well as a Partner in the corporate practice of the law firm of Wilson Sonsini Goodrich & Rosati, P.C. In addition to serving on the board of directors of Rezolute, he also serves on the board of directors of privately held Softhale NV in Belgium. Mr. Elam received his Juris Doctorate from Harvard Law School and a Bachelors of Arts from Howard University.
How old is Nevan Elam?
Nevan Elam is 51, he's been the Independent Director of Savara Inc since 2017. There are 9 older and 2 younger executives at Savara Inc. The oldest executive at Savara Inc is Richard Hawkins, 71, who is the Independent Director.
What's Nevan Elam's mailing address?
Nevan's mailing address filed with the SEC is ONE SUMMIT SQUARE,, 1717 LANGHORNE NEWTOWN ROAD, SUITE 300, LANGHORNE, PA, 19047.
Insiders trading at Savara Inc
Over the last 8 years, insiders at Savara Inc have traded over $2,203,958 worth of Savara Inc stock and bought 6,103,761 units worth $15,290,245 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Savara Inc executives and independent directors trade stock every 29 days with the average trade being worth of $348,922. The most recent stock trade was executed by Matthew Pauls on 28 December 2023, trading 84,000 units of SVRA stock currently worth $395,640.
What does Savara Inc do?
savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company’s lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara’s website at www.savarapharma.com or www.aerovanc.com
What does Savara Inc's logo look like?
Complete history of Mr. Elam stock trades at Nektar Therapeutics and Savara Inc
Savara Inc executives and stock owners
Savara Inc executives and other stock owners filed with the SEC include:
-
Dr. Badrul A. Chowdhury M.D., Ph.D.,
Chief Medical Officer -
David Lowrance,
Chief Financial Officer, Secretary -
David L. Lowrance,
CFO & Sec. -
Ricky Sun,
Independent Director -
Annigje van Es-Johansson,
Independent Director -
Badrul Chowdhury,
Chief Medical Officer -
Anne Erickson,
IR Contact Officer -
David Ramsay,
Independent Director -
Matthew Pauls,
Chairman of the Board, Interim Chief Executive Officer -
Joseph McCracken,
Independent Director -
Richard Hawkins,
Independent Director -
Nevan Elam,
Independent Director -
Dr. Peter Clarke Ph.D.,
Exec. VP of Global Technical Operations -
Charles LaPree,
Sr. VP of Global Regulatory Affairs & Quality Assurance -
Brian Maurer,
Head of Clinical Operations -
Dr. Dhaval Desai M.D.,
Head of Clinical Devel. -
Kate McCabe,
Sr. VP of Legal Affairs -
Robert N Neville,
Chief Executive Officer -
Yuri Pikover,
Director -
Jaakko Taneli Jouhikainen,
See Remarks -
Es Johansson An Van,
Director -
Forest Baskett,
10% owner -
Equity Opportunities 17, Ll...,
-
Rick Yang,
10% owner -
Paul Edward Walker,
10% owner -
Scott D Sandell,
10% owner -
Edward T Mathers,
10% owner -
Mohamad Makhzoumi,
10% owner -
Carmen Chang,
10% owner -
Anthony A. Jr. Florence,
10% owner -
Ali Behbahani,
10% owner -
Raymond Dennis Pratt,
Chief Medical Officer -
Robert Matthew Lutz,
Chief Operating Officer